title: Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy.
abstract: Nine pretreated patients aged >19 years with relapsed/refractory acute lymphoblastic leukemia (ALL) were treated with a combination of bortezomib plus chemotherapy before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Eight (88.9%) patients, including two Philadelphia chromosome-positive ALL patients, achieved a complete remission. Furthermore, the evaluable patients have benefited from allo-HSCT after response to this reinduction treatment. We conclude that bortezomib-based chemotherapy was highly effective for adults with refractory/relapsed ALL before allo-HSCT. Therefore, this regimen deserves a larger series within prospective trials to confirm these results.
authors.affiliation: Henan Key Lab of Experimental Haematology, Henan Institute of Haematology, Henan Tumor Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
authors.forename: Junmei
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Henan Key Lab of Experimental Haematology, Henan Institute of Haematology, Henan Tumor Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
authors.forename: Chao
authors.initials: C
authors.lastname: Wang
authors.affiliation: Henan Key Lab of Experimental Haematology, Henan Institute of Haematology, Henan Tumor Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
authors.forename: Yongping
authors.initials: Y
authors.lastname: Song
authors.affiliation: Henan Key Lab of Experimental Haematology, Henan Institute of Haematology, Henan Tumor Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
authors.forename: Yuzhang
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Henan Key Lab of Experimental Haematology, Henan Institute of Haematology, Henan Tumor Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
authors.forename: Baijun
authors.initials: B
authors.lastname: Fang
keywords: acute lymphoblastic leukemia; bortezomib; refractory; relapsed